Neuroectodermal Tumors, Primitive: Clinical Trials

573 completed, 140 recruiting, 104 terminated, 79 unknown. 422 Phase 1, 391 Phase 2, 84 Not applicable, 71 Phase 3, 25 Early Phase 1.

By phase and status

Phase	Trials	Status
Phase 1	422	Completed 241, Recruiting 56, Terminated 52, Active not recruiting 31, Withdrawn 18, Unknown 15, Not yet recruiting 5, Enrolling by invitation 2, Suspended 2
Phase 2	391	Completed 212, Recruiting 53, Terminated 43, Active not recruiting 31, Unknown 27, Withdrawn 15, Not yet recruiting 8, Enrolling by invitation 1, Suspended 1
Not applicable	84	Completed 41, Unknown 13, Recruiting 10, Withdrawn 9, Active not recruiting 4, Terminated 4, Not yet recruiting 2, Enrolling by invitation 1
Phase 3	71	Completed 40, Recruiting 10, Unknown 9, Terminated 7, Active not recruiting 2, Withdrawn 2, Not yet recruiting 1
Early Phase 1	25	Completed 6, Recruiting 6, Active not recruiting 5, Terminated 3, Unknown 3, Not yet recruiting 2
Phase 4	6	Active not recruiting 2, Completed 1, Not yet recruiting 1, Recruiting 1, Unknown 1

Follow Neuroectodermal Tumors, Primitive: new trials by email Literature Review of Neuroectodermal Tumors, Primitive trials Research Report on Neuroectodermal Tumors, Primitive

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography - Recurrent Ganglioneuroblastoma, Recurrent Neuroblastoma	Phase 1 / Phase 2	Recruiting	National Cancer Institute (NCI)	76	2027-06-25	2026-10-22
Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma Bridging Chemotherapy, Induction Cycles A1-A3, Induction Cycles A4-5 - Medulloblastoma	Phase 3	Not yet recruiting	Nationwide Children's Hospital	96	2027-01-01	2026-10-20
4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma GD2, PSMA and CD276 CAR-T cells - Neuroblastoma	Phase 1 / Phase 2	Not yet recruiting	Shenzhen Geno-Immune Medical Institute	100	2026-12-31	2026-09-01
NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab Radiation: 131I-MIBG, Dinutuximab, Vorinostat - Neuroblastoma	Phase 2	Not yet recruiting	New Approaches to Neuroblastoma Therapy Consortium	118	2026-12-31	2026-08-21
Haploidentical Donor Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Neuroblastoma CIML-NK Cells - Neuroblastoma	Phase 2	Recruiting	Children's Hospital Medical Center, Cincinnati	20	2026-12-01	2026-08-24
A Phase 2 Study Of Zanzalintinib For Patients With Recurrent Or Metastatic Olfactory Neuroblastoma Zanzalintinib - Metastatic Olfactory Neuroblastoma	Phase 2	Not yet recruiting	M.D. Anderson Cancer Center	16	2026-10-01	2026-10-05
Arsenic Trioxide Combined With Chemotherapy for Relapsed SHH-Activated and/or TP53-Mutant Medulloblastoma Arsenic Trioxide (ATO), ETOPOSIDE - Study, Cisplatin - Medulloblastoma	Phase 2	Not yet recruiting	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	78	2026-10-01	2026-10-02
PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma PEP-CMV vaccine, Tetanus booster, Nivolumab - Diffuse Midline Glioma, Diffuse Midline High-grade Glioma	Phase 1 / Phase 2	Suspended	Washington University School of Medicine	68	2026-09-30	2026-09-11
Comparing 123I-MIBG and 18F-MFBG Imaging in Patients With Newly Diagnosed, High Risk Neuroblastoma Biospecimen Collection, Computed Tomography, Florbenguane F18 - Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular	Phase 2	Withdrawn	Children's Oncology Group		2026-09-22	2026-09-16
Pharmacoscopy for Patients With Refractory Primary Brain Tumors Pharmacoscopy 1.0 - Brain (Nervous System) Cancers, Glioblastoma	Phase 2	Recruiting	University of Zurich	40	2026-09-11	2026-09-21
B7-H3.CD28Z.CART in CNS Neoplasms B7-H3.CD28Z.CART, Fludarabine, Cyclophosphamide - Central Nervous System Neoplasms, Brain Tumor	Phase 1	Recruiting	Robbie Majzner	70	2026-09-01	2026-09-03
Targeting MYC in High-Risk Medulloblastoma Tumor tissue collection - Medulloblastoma	Not applicable	Not yet recruiting	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	35	2026-09-01	2026-07-10
Study of CDK8 Inhibitor RVU120 in Combination With Everolimus in Children With Recurrent or Progressive Group 3 or 4 Medulloblastoma RVU120, Everolimus (Afinitor) tablets - Medulloblastoma Recurrent, Medulloblastoma	Phase 1	Not yet recruiting	Bożenna Dembowska Bagińska	48	2026-09-01	2026-10-08
B7-H3.CD28Z.CART in Solid Tumors B7-H3.CD28Z.CART, Fludarabine, Cyclophosphamide - Pediatric Solid Tumor, Neuroblastoma	Phase 1	Recruiting	Robbie Majzner	40	2026-08-24	2026-09-03
Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease Liothyronine (L-T3), Bevacizumab, Irinotecan - Medulloblastoma, Medulloblastoma, Childhood	Phase 1 / Phase 2	Recruiting	Sabine Mueller, MD, PhD	69	2026-08-21	2026-09-28
my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults my.naviGATE Digital Tool - Sarcoma, Osteosarcoma	Not applicable	Not yet recruiting	Dana-Farber Cancer Institute	143	2026-08-20	2026-04-08
Cognitive Rehabilitation for Survivors of Childhood Medulloblastoma Using Real Time Hemodynamic Neurofeedback rt fMRI Neurofeedback (DLPFC), rt fMRI Neurofeedback (PAC) - Medulloblastoma, Childhood, Survivorship	Not applicable	Recruiting	St. Jude Children's Research Hospital	40	2026-07-26	2026-09-23
Safety, Tolerability, and Preliminary Efficacy of [211At]MABG in Patients With Relapsed or Refractory Neuroblastoma [211At]MABG - Neuroblastoma (NB)	Early Phase 1	Recruiting	Sichuan University	10	2026-07-21	2026-08-21
AI-Assisted MRI Molecular Subtyping in Pediatric Brain Tumors Pediatric Brain Tumors, Glioma		Not yet recruiting	Huashan Hospital	1400	2026-07-15	2026-07-23
NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma i15.NKG2D.zeta NK cells and C7R.GD2.CARTs cells - Relapsed Neuroblastoma, Refractory Neuroblastoma	Phase 1	Recruiting	Baylor College of Medicine	27	2026-07-15	2026-07-21

Showing 20 of 1063. Sign in to see all of them.

Narrower conditions

Neuroblastoma (652)  ·  Medulloblastoma (314)  ·  Sarcoma (181)  ·  Osteosarcoma (146)  ·  Central Nervous System Neoplasms (145)  ·  Astrocytoma (135)  ·  Neuroectodermal Tumors, Primitive, Peripheral (134)  ·  Brain Neoplasms (133)  ·  Ependymoma (126)  ·  Glioma (126)  ·  Wilms Tumor (124)  ·  Neoplasms (111)  ·  Rhabdomyosarcoma (109)  ·  Oligodendroglioma (102)

Broader conditions

Neoplasms, Glandular and Epithelial (1062)  ·  Neoplasms, Nerve Tissue (1061)  ·  Neoplasms by Histologic Type (1059)  ·  Neoplasms, Neuroepithelial (1054)  ·  Neuroectodermal Tumors (1052)  ·  Neoplasms, Germ Cell and Embryonal (1030)  ·  Neoplasms (952)  ·  Neuroectodermal Tumors, Primitive, Peripheral (662)  ·  Neoplasms by Site (504)  ·  Nervous System Diseases (374)  ·  Nervous System Neoplasms (298)  ·  Neoplasms, Connective and Soft Tissue (291)  ·  Central Nervous System Diseases (230)  ·  Brain Diseases (223)

Interventions

Cyclophosphamide (148)  ·  Etoposide (98)  ·  Vincristine (87)  ·  Filgrastim (82)  ·  Carboplatin (80)  ·  Temozolomide (75)  ·  Radiotherapy (68)  ·  Cisplatin (65)  ·  Doxorubicin (61)  ·  Melphalan (57)  ·  Topotecan (55)  ·  Irinotecan (53)  ·  Isotretinoin (47)  ·  Peripheral Blood Stem Cell Transplantation (46)  ·  Granulocyte Colony-Stimulating Factor (41)

Sponsors

National Cancer Institute (NCI) (133)  ·  Children's Oncology Group (86)  ·  Memorial Sloan Kettering Cancer Center (62)  ·  St. Jude Children's Research Hospital (35)  ·  New Approaches to Neuroblastoma Therapy Consortium (24)  ·  Giselle Sholler (19)  ·  Children's Cancer and Leukaemia Group (17)  ·  M.D. Anderson Cancer Center (17)  ·  Fred Hutchinson Cancer Center (16)  ·  Novartis Pharmaceuticals (16)  ·  Pediatric Brain Tumor Consortium (16)  ·  Baylor College of Medicine (15)  ·  City of Hope Medical Center (14)  ·  Dana-Farber Cancer Institute (14)  ·  Emory University (9)

Countries

United States (774)  ·  Canada (134)  ·  Australia (80)  ·  France (75)  ·  United Kingdom (71)  ·  Italy (54)  ·  Spain (52)  ·  China (51)  ·  Germany (50)  ·  Puerto Rico (47)  ·  Switzerland (47)  ·  Netherlands (40)  ·  New Zealand (29)  ·  Austria (25)  ·  Belgium (24)

Top investigators

Giselle Sholler, MD (14)  ·  Brian Kushner, MD (11)  ·  Brian H. Kushner, MD (8)  ·  Nai-Kong V. Cheung, MD, PhD (8)  ·  Shakeel Modak, MD (8)  ·  Katherine K. Matthay, MD (6)  ·  Kenneth G. Lucas, MD (6)  ·  Darell D. Bigner, MD, PhD (5)  ·  Elizabeth Fox, MD (5)  ·  Frank Berthold, MD (5)  ·  John M. Maris, MD (5)  ·  Steven DuBois, MD (5)  ·  Yizhuo Zhang (5)  ·  Amar Gajjar (4)

Results publications

PMID 31401903, PMID 23633099, PMID 17369569, PMID 19171714, PMID 19556464, PMID 19805691, PMID 20567002, PMID 20847174, PMID 20879881, PMID 22682017, PMID 25209242, PMID 26169613, PMID 27465021, PMID 29343557, PMID 32719487, PMID 34028986, PMID 34435684, PMID 34486544, PMID 37640679, PMID 37883734, PMID 38917371, PMID 40073837, PMID 40721826, PMID 40967259, PMID 41920422, PMID 10706954, PMID 10797354, PMID 10882162, PMID 11118469, PMID 11410496, PMID 11464889, PMID 11835236, PMID 11857322, PMID 11904735, PMID 12091876, PMID 12101494, PMID 12165894, PMID 12218188, PMID 12525530, PMID 12658506, PMID 12721262, PMID 12880954, PMID 12932669, PMID 14767498, PMID 15033677, PMID 15163307, PMID 15269160, PMID 15337804, PMID 15459300, PMID 1576319

NIH funding

U10CA098543 (39), U10CA180886 (37), U01CA081457 (17), P01CA081403 (16), P30CA008748 (10), P30CA033572 (10), P30CA068485 (10), U01CA097452 (10), UM1CA081457 (10), 2023 (6), P30CA043703 (6), UM1CA097452 (5), P30CA022453 (4), U01CA069856 (4), UM1CA228823 (4)